Articles tagged with Antiangiogenic Therapy
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
The foundation awarded $400,000 over two years to five early-career researchers and continuation support to three current Innovators with significant progress on their proposed research. The recipients focus on developing targeted therapeutics, decoding dendritic cell function, defining NKT cell interactions with tumors, engineering T ...
Experts warn that new drugs for advanced breast cancer are unaffordable and may lead to unequal treatment access worldwide. The consensus panel recommended prioritizing most effective treatments and using next-generation sequencing for personalized medicine.
A team led by University of Houston engineer Tianfu Wu aims to find better biomarkers for ovarian cancer using autoantibodies and machine learning. By detecting ovarian cancer earlier, mortality rates could be reduced by 10-30%.
The University of Texas at Arlington's nursing and physics team has developed a system to study alpha radiation, improving the effectiveness of radiation therapy. The team's research was recognized with the Best in Physics award at the American Association of Physicists in Medicine's annual meeting.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.
Researchers tested tivozanib with nivolumab in patients with advanced clear cell renal cell carcinoma and found no benefit from combining the two treatments. Repeat ICI therapy should be discouraged due to lack of improvement in overall survival or response rates.
A pivotal study supports belzutifan approval for patients with advanced kidney cancer, with belzutifan demonstrating a 25% lower risk of progression compared to everolimus. The HIF-2 inhibitor offers a novel therapeutic mechanism in advanced renal cell carcinoma treatment.
Researchers highlight the need to develop new anti-angiogenic agents to improve cancer treatment efficacy, citing knowledge gaps in human clinical trials. The review recommends considering tumor mutations, microenvironment, and patient profiles to select optimal AAD combinations.
A new trial found that combining anti-angiogenic drugs with chemotherapy led to more young people seeing their tumors shrink, from 18% in the control group to 26%. Patients who received Bevacizumab additionally had better one year progression-free survival rates.
Researchers have developed a light-activatable prodrug nanomedicine that combines anti-angiogenic and photodynamic therapy to treat wet AMD. The treatment is minimally invasive and shows excellent therapeutic efficacy without side effects.
A phase 3 clinical trial found belzutifan significantly reduces the risk of progression in patients with metastatic clear cell renal cell carcinoma who had previously treated with immune checkpoint inhibitors and anti-angiogenic therapies. The drug demonstrated improved progression-free survival, higher overall response rates, and redu...
Researchers investigated the effects of everolimus on the STAT3/HIF-1α/VEGF pathway in TP53 mutant cell lines and xenograft models. Everolimus treatment significantly inhibited cell growth and reduced tumor angiogenesis and lymphangiogenesis.
Researchers at Massachusetts General Hospital developed two approaches to repair tumor blood vessels, alleviating hypoxia and improving chemotherapy's effectiveness. Combining these approaches may create a more powerful anti-cancer strategy.
Despite its promise, cancer immunotherapy faces several hurdles, including limited efficacy and variable outcomes. Researchers are exploring new therapeutic targets and combination strategies to overcome resistance and improve patient outcomes.
A study found that 50% of metastatic colorectal cancer patients treated with bevacizumab experienced RAS mutation disappearance, suggesting the drug's potential to revert tumors. This discovery may open new therapeutic avenues for primarily RAS mutant patients.
Researchers found that antiangiogenic therapy can increase the invasiveness of kidney tumors and induce a poor prognosis. A new biomarker, ALDH1A3, has been identified to predict patient response to treatment.
This issue of Acta Pharmaceutica Sinica B features three original research articles exploring novel mechanisms and treatments for various diseases, including cerebral ischemia-reperfusion injury, anti-atherosclerosis, and breast cancer. The articles discuss the potential benefits of IL-4 supplementation, berberine's gut-absorption-enha...
L-Grb2 antisense oligodeoxynucleotide (L-Grb2) has promising antitumor activity in preclinical models of ovarian and uterine carcinoma, reducing angiogenesis and increasing apoptosis. L-Grb2's therapeutic efficacy suggests a potential new target for cancer treatment.
Research found that higher levels of sBTLA proteins were associated with poorer overall survival in patients with advanced liver cancer. Treatment with sorafenib revealed dynamic changes in soluble checkpoint protein levels, suggesting potential use as a biomarker for predicting patient outcomes.
A new enzyme-linked immunosorbent assay (ELISA) for bioanalysis of bevacizumab has been developed with a high sensitivity and selectivity. The assay limits detection to 1.01 ng/mL and offers an effective working dynamic range of 3.07-100 ng/mL.
A Massachusetts General Hospital research team found that anti-angiogenic drugs induce a microenvironment that suppresses immune systems actions, allowing tumors to grow. Developing a potential strategy to overcome this mechanism, the researchers identified CX3CL1 as an attractive target for immunotherapy.
Combining anti-angiogenic and immune-stimulating therapies creates specialized blood vessels that deliver cancer-fighting immune cells to tumors, leading to better therapeutic outcomes. This breakthrough research may improve treatments and prolong survival periods for patients.
Nintedanib significantly improves median progression-free survival compared to placebo, with disease control improved by 26% compared to 11% in the placebo group. However, overall survival did not differ between the two groups.
Researchers at the University of Texas MD Anderson Cancer Center demonstrated a significant median overall survival benefit with nivolumab, increasing it to 25 months compared to 19.6 months for everolimus. The study also showed a higher objective response rate and fewer treatment-related adverse events with nivolumab.
Researchers discovered that myeloid cells switch roles and become anti-therapy agents when angiogenesis inhibitors are used, leading to tumor growth and relapse. Targeting the PI3K signaling pathway may offer a way to prevent this phenomenon.
In a Phase III study, lenvatinib showed dramatic improvement in progression-free survival for patients with advanced radioiodine-refractory thyroid cancer. The therapy significantly improved overall response rate and survival rates compared to placebo.
The Champalimaud Award recognizes the development of Anti-Angiogenic Therapy for Retinal Disease, which has improved vision in patients with devastating blindness diseases. The treatment targets age-related macular degeneration and diabetic retinopathy, conditions affecting millions worldwide.
Researchers found that combining CT imaging findings with baseline serum lactate dehydrogenase levels can accurately predict patient survival. Patients with low baseline serum LDH and evidence of tumor devascularization on their initial post-therapy CT scans are likely to have a favorable response to therapy.
Researchers have found that blocking the immune response can enhance viral therapy against solid tumors, leading to a 90% cure rate in mouse models. The study suggests combining oncolytic viruses with anti-VEGF therapies could be an effective treatment strategy for certain types of cancer.
Scientists found that Ang-2 regulates angiogenesis through TIE-2 and integrin signaling, leading to two independent effects on tumor blood vessels. This discovery prompts the development of new therapies targeting Ang-2.
Researchers at CNIO have discovered a new target for developing anti-angiogenic and anti-tumoral therapies. The protein ephrinB2 was found to play a crucial role in angiogenesis and lymphoangiogenesis, processes that promote tumour growth and metastasis.
The addition of bevacizumab to trastuzumab and docetaxel improved progression-free survival in patients with HER2-positive, locally recurrent/metastatic breast cancer. Median progression-free survival increased by 2.8-2.9 months with bevacizumab.
The foundation awarded grants to eight young clinical investigators to support their cancer research programs, with a focus on developing new treatments and improving patient quality of life. The awards total $3.1 million and will provide funding for three years, with some recipients also receiving continuation grants.
Researchers used NBI to visualize mucosal angiogenesis in IBD patients and found abnormal microvascular changes not seen with white light colonoscopy. This technology may aid in assessing mucosal angiogenesis and could be beneficial for IBD treatment.
Researchers identified a new biomarker that can predict which patients with recurrent glioblastoma will respond better to anti-vascular endothelial growth factor therapy. The study found that vascular normalization, measured using advanced MRI and blood biomarkers, correlated with survival rates.
A study found that sorafenib dramatically improved the condition of rats with portal hypertension, reducing new blood vessel growth and improving liver function. The results suggest that sorafenib may be an effective therapeutic agent for treating advanced portal hypertension.
Scientists at Karolinska Institutet identified a crucial role of Dll4 in blood vessel formation through angiogenesis. The study found that Dll4 signalling determines the number of sprouts and branches formed, which is essential for tissue health and disease prevention.
A new study published in PNAS shows that combining anti-angiogenic agents can increase the effectiveness of treatment for tumors and retinopathy. The therapy, which targets multiple angiogenic pathways, resulted in complete inhibition of pathological neovascularization in over 60% of treated eyes.
Researchers found that combining imantanib with apoptosis-inducing drugs inhibits tumor growth more effectively than either therapy alone. The combination increased sensitivity to TRAIL, a drug that induces cell death, leading to reduced pulmonary metastases and primary tumor growth.
A Phase III trial demonstrated a significant increase in average time to progression with sunitinib treatment compared to placebo, leading to improved overall survival. Treatment with sunitinib was well-tolerated, with common side effects including fatigue and diarrhoea.
Researchers discover that CA4P selectively targets endothelial cells, inducing regression of unstable blood vessels by disrupting VE-cadherin signaling. This breakthrough could lead to new avenues for targeting tumor neo-vessels and increasing the therapeutic window of anti-angiogenic agents.
Researchers found that levels of circulating endothelial cells and progenitor cells correlate with tumor blood vessel growth and response to antiangiogenic therapy. Measuring these cells could be a reliable surrogate for therapeutic inhibition of angiogenesis.
A new study published in Cancer Cell reveals that combining radiation with antiangiogenic therapy can significantly slow tumor growth when administered at the right time. The research found that a unique time period exists during which this combination is most effective, making it a potential breakthrough in cancer treatment.
Researchers at Mayo Clinic found that celecoxib reduces mammary gland tumor mass through apoptosis and regulates prostaglandin pathways. The study suggests celecoxib may be used to prevent and treat breast tumors.
A study found that the GSTP1 polymorphism was associated with increased survival in patients with advanced colorectal cancer who received platinum-based chemotherapy. Meanwhile, research on human herpesvirus-8 suggested that the K1 gene may play a role in malignant transformation.